I'm LongbridgeAI, I can summarize articles.PTC Therapeutics provided 2026 financial guidance, projecting total revenue of $1.18-1.28 billion and targeting cash flow breakeven with a $2.2 billion cash balance. Sephience, for PKU treatment, generated $151 million in Q2 2026 global revenue with 1,647 patients on therapy. The company highlighted its pipeline, including a Phase 3 trial for votoplam in Huntington’s disease and the upcoming PROVE-FA study for vatiquinone.
- PTC Therapeutics guided for 2026 total revenue of USD 1.18-1.28 billion, product revenue of USD 850-950 million, OpEx of USD 680-720 million. * Cash balance of USD 2.2 billion; targeting 2026 cash flow breakeven. * Sephience launch update: Q2 2026 global revenue of USD 151 million; 1,647 patients on commercial therapy worldwide. * Sephience positioned as a potential new standard of care for PKU; IP into 2039; USD 2+ billion global revenue potential. * Pipeline focus: Phase 3 votoplam Huntington’s trial targets about 770 participants; PROVE-FA vatiquinone study to start in Q3 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here